The Experts below are selected from a list of 34794 Experts worldwide ranked by ideXlab platform

Kenneth M Kaye - One of the best experts on this subject based on the ideXlab platform.

  • newer beta lactam Antibiotics doripenem ceftobiprole ceftaroline and cefepime
    Medical Clinics of North America, 2011
    Co-Authors: Jose A Bazan, Stanley I Martin, Kenneth M Kaye
    Abstract:

    : This article reviews the new Beta-Lactam (β-lactam) Antibiotics doripenem, ceftobiprole, and ceftaroline. It covers pharmacokinetic and pharmacodynamic properties, dosing, in vitro activities, safety, and clinical trial results. Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. Ceftaroline has received FDA approval for the treatment of skin and soft tissue infections and community acquired pneumonia. Ceftobiprole has not received FDA approval. The article also reviews recent data suggesting increased overall mortality with Cefepime (Maxipime) use compared with other Beta-Lactam Antibiotics and the potential risk for neurotoxicity in the setting of renal failure.

  • newer beta lactam Antibiotics doripenem ceftobiprole ceftaroline and cefepime
    Infectious Disease Clinics of North America, 2009
    Co-Authors: Jose A Bazan, Stanley I Martin, Kenneth M Kaye
    Abstract:

    : This article reviews the new Beta-Lactam (Beta-Lactam) Antibiotics doripenem, ceftobiprole, and ceftaroline. It covers pharmacokinetic and pharmacodynamic properties, dosing, in vitro activities, safety, and clinical trial results. Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. At this writing, ceftobiprole is under review by the FDA for approval based on results of phase 3 clinical trials, whereas at least one phase 3 clinical trial of ceftaroline has been completed. The article also reviews recent data suggesting increased overall mortality with Cefepime (Maxipime) use compared with other Beta-Lactam Antibiotics and the potential risk for neurotoxicity in the setting of renal failure.

Raymond Auckenthaler - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics and pharmacodynamics of oral Beta-Lactam Antibiotics as a two-dimensional approach to their efficacy.
    The Journal of antimicrobial chemotherapy, 2002
    Co-Authors: Raymond Auckenthaler
    Abstract:

    Pharmacokinetic and pharmacodynamic parameters are increasingly recognized as important determinants of the therapeutic efficacy of an antibiotic. For Beta-Lactam Antibiotics, the most important determinant of the antimicrobial efficacy, and hence predictor of therapeutic efficacy, is the length of time that serum concentrations exceed the MIC. Dosing schedules for Beta-Lactam Antibiotics should maintain serum concentrations above the MIC for the bacterial pathogen for at least 50% of the dosing interval to achieve therapeutic efficacy and prevent the development of resistance. This is a basic criterion for the clinical efficacy of Beta-Lactams. A combination of microbiological activity and pharmacokinetic characteristics was applied to calculate the time that serum antibiotic concentrations exceed the MIC for the major respiratory tract pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes and Klebsiella pneumoniae. In contrast with some other oral Beta-Lactam Antibiotics, cefpodoxime 200 mg bd maintains serum concentrations above the MIC for each organism for at least 50% of the dosing interval and may therefore be an attractive choice for empirical therapy of community-acquired lower respiratory tract infections.

J D Williams - One of the best experts on this subject based on the ideXlab platform.

  • Beta-Lactam Antibiotics in respiratory tract infections.
    International journal of antimicrobial agents, 1993
    Co-Authors: J D Williams
    Abstract:

    Beta-Lactam Antibiotics have played a major role in the treatment of respiratory infections for many years. The use of the three main groups of Beta-Lactam Antibiotics-penicillins, cephalosporins and non-classical Beta-Lactams-in respiratory infections is reviewed. Their development and efficacy have more or less kept pace with the changes in microbial resistance, emergence of new pathogens and changes in medical practice. Consequently, Beta-Lactam agents continue to make a valuable contribution to therapy of respiratory tract infections.

Luís Carlos De Souza Ferreira - One of the best experts on this subject based on the ideXlab platform.

  • Interactions of Yersinia pestis penicillin-binding proteins with Beta-Lactam Antibiotics.
    Antimicrobial agents and chemotherapy, 1995
    Co-Authors: R. C. C. Ferreira, J. T. Park, Douglas C. Camelo, D. F. De Almeida, Luís Carlos De Souza Ferreira
    Abstract:

    The affinities of six major penicillin-binding proteins (PBPs) of Yersinia pestis EV76 to different Beta-Lactam Antibiotics were determined. The results indicate that, similar to their counterparts in Escherichia coli, PBP2 and PBP3 are the lethal targets of amdinocillin and furazlocillin, respectively. The PBP contents of four additional Y. pestis strains and the morphological effects produced by some Beta-Lactam Antibiotics are also reported.

W R Byrne - One of the best experts on this subject based on the ideXlab platform.

  • Bacterial filamentation of Yersinia pestis by Beta-Lactam Antibiotics in experimentally infected mice.
    Archives of pathology & laboratory medicine, 1997
    Co-Authors: Kelly J. Davis, Peter Vogel, David L. Fritz, Keith E. Steele, M. L. Pitt, S L Welkos, A. M. Friedlander, W R Byrne
    Abstract:

    Objective To identify alternatives to streptomycin for treating pneumonic plague, we evaluated Beta-Lactam Antibiotics to treat experimental pneumonic plague in mice. Methods Mice were exposed to a lethal inhaled dose of Yersinia pestis and treated with Beta-Lactam Antibiotics administered every 6 hours, starting 42 hours postexposure. Results The mice died or were euthanized in extremis 3 days postexposure. We observed marked bacterial filamentation of Y pestis in the tissues of mice treated with ceftazidime (10/10 mice), aztreonam (9/10 mice), or ampicillin (1/10 mice), but not in the tissues of mice treated with cefotetan, cefazolin, ceftriaxone, or saline. There was no evidence of septation of the filamentous bacteria by light or electron microscopy. The filamentous bacteria were confirmed as Y pestis based on their reactivity with rabbit anti-Y pestis F1 serum. Conclusions Marked bacterial filamentation of Y pestis can be produced in vivo by certain Beta-Lactam Antibiotics. This antibiotic-induced morphologic change is important because filamentous bacteria in clinical samples could possibly be confused with filamentous actinomycotic organisms.